Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity in a report released on Friday.

A number of other research analysts also recently commented on the company. Mizuho reaffirmed a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 target price on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 28th. HC Wainwright set a $69.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company’s stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average target price of $66.36.

Shares of Aerie Pharmaceuticals (NASDAQ AERI) opened at 50.95 on Friday. Aerie Pharmaceuticals has a 52 week low of $32.05 and a 52 week high of $61.30. The stock’s market cap is $1.85 billion. The firm has a 50-day moving average price of $54.83 and a 200-day moving average price of $50.04.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. On average, analysts forecast that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Aerie Pharmaceuticals, Inc. (AERI) Rating Reiterated by Canaccord Genuity” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/24/aerie-pharmaceuticals-inc-aeri-rating-reiterated-by-canaccord-genuity.html.

Institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its stake in Aerie Pharmaceuticals by 28.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after acquiring an additional 49,473 shares in the last quarter. AXA bought a new stake in Aerie Pharmaceuticals during the 2nd quarter valued at $10,961,000. BlackRock Inc. raised its stake in Aerie Pharmaceuticals by 113,376.8% during the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after acquiring an additional 2,598,596 shares in the last quarter. Boulegeris Investments Inc. raised its stake in Aerie Pharmaceuticals by 5.2% during the 2nd quarter. Boulegeris Investments Inc. now owns 79,525 shares of the company’s stock valued at $4,179,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Aerie Pharmaceuticals by 5.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after acquiring an additional 3,739 shares in the last quarter. 94.64% of the stock is currently owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.